Clinical Trial Update: Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update on ocrelizumab in relapsing-remitting multiple sclerosis, describing its effects on immune cells in lymph nodes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: University of California, San Francisco | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 4 | Status: ENROLLING_BY_INVITATION